CO2019005993A2 - Pirrolopirimidinas como potenciadores de cftr - Google Patents

Pirrolopirimidinas como potenciadores de cftr

Info

Publication number
CO2019005993A2
CO2019005993A2 CONC2019/0005993A CO2019005993A CO2019005993A2 CO 2019005993 A2 CO2019005993 A2 CO 2019005993A2 CO 2019005993 A CO2019005993 A CO 2019005993A CO 2019005993 A2 CO2019005993 A2 CO 2019005993A2
Authority
CO
Colombia
Prior art keywords
compounds
cftr
cystic fibrosis
enhancers
pyrrolopyrimidines
Prior art date
Application number
CONC2019/0005993A
Other languages
English (en)
Inventor
Joseph Walter Strohbach
David Christopher Limburg
John Paul Mathias
Atli Thorarensen
Rajiah Aldrin Denny
Christoph Wolfgang Zapf
Daniel Elbaum
Lori Krim Gavrin
Ivan Viktorovich Efremov
Original Assignee
Cystic Fibrosis Found Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found Therapeutics Inc filed Critical Cystic Fibrosis Found Therapeutics Inc
Publication of CO2019005993A2 publication Critical patent/CO2019005993A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

RESUMEN La presente invención se refiere a compuestos de la Fórmula I, I en donde R1a, R1b, R2, R3, R4, W, Y y Z son como se describen en este documento, y a sales farmacéuticamente aceptable de los mismos. Los compuestos son potenciadores del regulador de conductancia transmembranal de la fibrosis quística (CFTR). La invención también da a conocer composiciones farmacéuticas que comprenden el compuesto opcionalmente en combinación con agentes terapéuticos adicionales, y métodos de potenciación, en mamíferos incluyendo humanos, de CFTR por la administración de los compuestos. Estos compuestos son útiles para el tratamiento de fibrosis quística (CF), asma, bronquiectasia, enfermedad pulmonar obstructiva crónica (COPD), constipación, diabetes mellitus, xeroftalmia, pancreatitis, rinosinusitis, síndrome de Sjögren y otros trastornos asociados con CFTR.
CONC2019/0005993A 2016-11-18 2019-06-07 Pirrolopirimidinas como potenciadores de cftr CO2019005993A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Publications (1)

Publication Number Publication Date
CO2019005993A2 true CO2019005993A2 (es) 2019-07-31

Family

ID=62144793

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005993A CO2019005993A2 (es) 2016-11-18 2019-06-07 Pirrolopirimidinas como potenciadores de cftr

Country Status (21)

Country Link
US (5) US10301315B2 (es)
EP (1) EP3541390B1 (es)
JP (3) JP6978507B2 (es)
KR (2) KR20230146104A (es)
CN (2) CN115850268A (es)
AU (2) AU2017362350B2 (es)
BR (1) BR112019010167A2 (es)
CA (1) CA3044050A1 (es)
CL (1) CL2019001334A1 (es)
CO (1) CO2019005993A2 (es)
CR (1) CR20190292A (es)
DO (1) DOP2019000126A (es)
EC (1) ECSP19043120A (es)
IL (2) IL296279A (es)
MX (2) MX2019005822A (es)
PE (1) PE20200739A1 (es)
PH (1) PH12019501098A1 (es)
RU (2) RU2757457C2 (es)
SG (1) SG10202106949XA (es)
UA (1) UA125400C2 (es)
WO (1) WO2018094137A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698782B1 (en) 2012-01-06 2024-05-15 H. Lundbeck A/S Carbamate compounds for use in therapy
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
MA44126A (fr) * 2015-12-22 2018-10-31 Proteostasis Therapeutics Inc Méthodes de traitement de maladies et troubles pulmonaires
EP3519401B1 (en) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MX2019005822A (es) * 2016-11-18 2019-09-09 Cystic Fibrosis Found Therapeutics Inc Pirrolopirimidinas como potenciadores de cftr.
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
BR112019012335A2 (pt) * 2016-12-16 2020-03-03 Cystic Fibrosis Foundation Therapeutics, Inc. Derivados de heteroarila bicíclica como potenciadores de cftr
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN113891744A (zh) * 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
CN114007616A (zh) 2019-07-15 2022-02-01 诺华股份有限公司 (s)-3-氨基-6-甲氧基-n-(3，3，3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
JP2004534779A (ja) 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
AU2007226344A1 (en) * 2006-03-11 2007-09-20 Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives used as HSP90 inhibitors
NZ571182A (en) * 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
US20130123281A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
MX2019005822A (es) 2016-11-18 2019-09-09 Cystic Fibrosis Found Therapeutics Inc Pirrolopirimidinas como potenciadores de cftr.

Also Published As

Publication number Publication date
JP6978507B2 (ja) 2021-12-08
KR20190110088A (ko) 2019-09-27
PH12019501098A1 (en) 2019-09-09
BR112019010167A2 (pt) 2019-09-17
JP2020510668A (ja) 2020-04-09
CN110337294A (zh) 2019-10-15
US20190225621A1 (en) 2019-07-25
CL2019001334A1 (es) 2019-11-15
AU2022201816B2 (en) 2024-02-15
CN115850268A (zh) 2023-03-28
IL266668A (en) 2019-07-31
MX2019005822A (es) 2019-09-09
UA125400C2 (uk) 2022-03-02
AU2017362350A1 (en) 2019-06-20
RU2019118623A3 (es) 2021-03-18
US10494374B2 (en) 2019-12-03
RU2019118623A (ru) 2020-12-21
US10301315B2 (en) 2019-05-28
DOP2019000126A (es) 2019-08-30
IL266668B (en) 2022-10-01
PE20200739A1 (es) 2020-07-24
JP2022024023A (ja) 2022-02-08
CN110337294B (zh) 2022-11-01
US20230250100A1 (en) 2023-08-10
US20210171534A1 (en) 2021-06-10
AU2022201816A1 (en) 2022-04-07
MX2021012639A (es) 2022-10-03
CA3044050A1 (en) 2018-05-24
SG10202106949XA (en) 2021-07-29
IL296279A (en) 2022-11-01
KR102585398B1 (ko) 2023-10-10
IL266668B2 (en) 2023-02-01
RU2021129721A (ru) 2021-11-26
ECSP19043120A (es) 2019-08-30
WO2018094137A1 (en) 2018-05-24
EP3541390A1 (en) 2019-09-25
JP7360434B2 (ja) 2023-10-12
JP2023182694A (ja) 2023-12-26
EP3541390B1 (en) 2024-05-01
US20200017512A1 (en) 2020-01-16
KR20230146104A (ko) 2023-10-18
RU2757457C2 (ru) 2021-10-18
AU2022201816A8 (en) 2022-04-21
CR20190292A (es) 2019-09-03
AU2017362350B2 (en) 2021-12-23
US20180141954A1 (en) 2018-05-24
EP3541390A4 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
CO2019005993A2 (es) Pirrolopirimidinas como potenciadores de cftr
MX2019007135A (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
CO2018000413A2 (es) Tricíclicos sustituidos
CU20120139A7 (es) Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf)
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
BR112018007145A2 (pt) ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
ECSP16054826A (es) Derivados Novedosos de Amino Pirimidina
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
PA8774101A1 (es) Compuesto de pirmidina
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
CL2008001898A1 (es) Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma.
CR20120062A (es) Terapia combinada para el tratamiento de la diabetes
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BR112014016648A8 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
EA202092976A1 (ru) Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
PA8628301A1 (es) Derivados sustituidos de diaza-espiro-[4.5]-decano y su uso como antagonistas de neuroquininas
SV2006002059A (es) Compuestos para el tratamiento de enfermedades ref. pc32232a